Related by context. All words. (Click for frequent words.) 77 preclinical efficacy 73 candidate CRLX# 73 IMA# 73 pharmacokinetic PK study 72 GRN# 72 CCX# 72 phase IIa clinical 72 nanopharmaceutical 71 Phase 1a clinical 71 RGB # 71 metaglidasen 71 Phase Ib study 71 HQK 71 HuMax EGFr 71 Quinamed 71 Virulizin ® 71 oral prodrug 71 PEG SN# 70 preclinically 70 fosbretabulin 70 CR# vcMMAE 70 mertansine 70 R#/MEM # 70 Archexin 70 Phase 1b trial 70 davunetide intranasal AL 70 Sym# 70 ENMD # 70 Alocrest 70 GVAX ® 70 JAK2 inhibitor 70 alvespimycin 70 HuMax CD#b 69 HGS# 69 INCB# [001] 69 Phase Ib II 69 CYT# potent vascular disrupting 69 oral picoplatin 69 Novolimus 69 GAMMAGARD 69 OHR/AVR# 69 phase IIa 69 demonstrated antitumor activity 69 IRX 2 69 phase IIb study 69 CCR9 antagonist 69 OvaRex R 69 PSMA ADC 69 radezolid 69 entinostat 69 YONDELIS 69 CD# CEA 69 Phase Ib clinical 69 cannabinor 68 Trofex 68 cediranib 68 DermaVir Patch 68 Triapine 68 PXD# 68 relapsed MM 68 Symadex 68 Phase 1b clinical trials 68 CBLC# 68 Factor VIIa 68 PORxin TM platforms 68 neratinib 68 Carfilzomib 68 ISIS # 68 vidofludimus 68 basal bolus regimen 68 Traficet EN 68 Xanafide 68 Panzem R NCD 68 forodesine 68 Phase 2a trial 68 Phase Ia 68 including eniluracil ADH 68 CINQUIL 68 Tarvacin TM 68 evaluating tivozanib 68 trodusquemine 68 Tyrima 68 DXL# 68 Bezielle 68 Azedra 68 liposomal formulation 68 Phase #/#a 68 BrachySil TM 68 PROSTVAC TM 68 delafloxacin 68 RLY# 68 OMP #M# 68 farletuzumab 68 obatoclax 68 trastuzumab DM1 T DM1 68 depsipeptide 67 Myocet 67 PEGylated interferon 67 PRT# 67 therapeutic monoclonal antibody 67 anticoagulant reversing agent 67 IMC #B 67 MAGE A3 ASCI 67 TRO# 67 BGC# 67 vivo preclinical 67 ALN VSP 67 Tesetaxel 67 teriflunomide 67 multicenter Phase II 67 pertuzumab 67 GRNVAC1 67 tubulin inhibitor 67 ELACYT 67 Zalypsis 67 Guanilib 67 ESBA# 67 Omacetaxine 67 TEMSO 67 Phase IIa trials 67 PROSTVAC VF 67 PHX# 67 Aplidin 67 Romidepsin 67 pharmacokinetic pharmacodynamic 67 Phase #b/#a clinical 67 oral talactoferrin 67 ganetespib 67 phase IIb clinical 67 Capesaris 67 favorable pharmacokinetic profile 67 antiangiogenic agents 67 clevidipine 67 Phase 2a 67 elotuzumab 67 phase IIb 67 Zemplar Capsules 67 Safinamide 67 MEK inhibitors 67 Phase IIb clinical trials 67 enzastaurin 67 phase 2a 67 cilengitide 67 HCV protease inhibitors 67 PI3K/Akt pathway inhibitor 67 GW# [003] 67 Androxal TM 67 evaluating mipomersen 67 Phase #b/#a trial 67 Neuradiab TM 67 Cloretazine ® 67 immune modulating 67 GLP toxicology studies 67 Azedra TM 66 Phase 2a clinical 66 R roscovitine 66 NP2 Enkephalin 66 PDE4 inhibitor 66 Pertuzumab 66 selective androgen receptor modulator 66 mGluR2 NAM 66 PNT# 66 Mipomersen 66 Trofex TM 66 riociguat 66 Pimavanserin 66 telomerase therapeutic 66 deforolimus 66 huC# DM4 66 ZK EPO 66 Annamycin 66 Ceflatonin R 66 brivaracetam 66 CIMZIA ™ 66 TPI ASM8 66 peptide conjugated 66 Elotuzumab 66 TACI Ig 66 PORxin TM 66 huN# DM1 66 Phase 2b Clinical Trial 66 VersaFilm 66 oral rivaroxaban 66 multitargeted 66 Phase IIa trial 66 leading oral taxane 66 CTAP# Capsules 66 Squalamine 66 antisense inhibitors 66 Combination REOLYSIN R 66 maximally tolerated dose 66 Litx 66 Ostabolin C 66 Tarceva TM 66 EGS# 66 ATL# [001] 66 CRMD# 66 ZACTIMA 66 AAG geldanamycin analog 66 ProSavin 66 TG# [003] 66 TBC# 66 Cloretazine VNP#M 66 rxRNA 66 novel VDA molecule 66 AS# amonafide L malate 66 LymphoStat B TM 66 HDL Mimetic Peptide 66 vascular disrupting agent 66 elacytarabine 66 OvaRex MAb 66 novel oral anticoagulant 66 generation URAT1 inhibitor 66 Hsp# Inhibitor 66 OncoVEX 66 INSPIRE Trial Phase III 66 Solazed TM 66 midstage clinical 66 preclinical pharmacokinetic 66 velafermin 66 Bayer HealthCare Onyx Pharmaceuticals 66 Exherin TM 66 MKC# MKC# PP 66 PRTX 66 vinca alkaloid 66 galiximab 66 indibulin 66 rALLy clinical trial 66 telomerase inhibitor drug 66 Sapacitabine 66 haematological cancers 66 Aplidin R 66 ALN TTR 66 pomalidomide 66 ChronVac C R 66 pan HDAC inhibitor 66 Zybrestat 66 HCV protease inhibitor 66 Exelixis compounds 66 p# inhibitor 66 Phase #b/#a 66 Vascugel ® 66 AKT inhibitor 66 SinuNase ™ 66 PGL# 66 Panzem NCD 66 randomized Phase IIb 66 intraoperative radiotherapy 66 orally administered inhibitor 66 Phase #/#a trial 66 CEQ# 66 phase IIb trial 66 BRAF inhibitor 66 vascular disrupting agents 65 cMET 65 Phase 2b clinical trials 65 kidney urologic 65 Plicera 65 Kahalalide F 65 non nucleoside inhibitor 65 EXPAREL TM 65 Alzhemed TM 65 oral taxane 65 EDEMA3 trial 65 systemically administered 65 next generation URAT1 65 budesonide foam 65 XmAb 65 CHAMPION PCI 65 ulimorelin 65 Cloretazine 65 alemtuzumab Campath 65 AEG# 65 immatics 65 XL# XL# 65 Ophena TM 65 Blinatumomab 65 MYDICAR ® 65 PSN# [002] 65 Elagolix 65 Marqibo TM 65 regorafenib 65 Glufosfamide 65 triphendiol 65 Phase III ADT 65 Vascugel R 65 LibiGel ® 65 phase Ib 65 Tarvacin Anti Cancer 65 FOLFOX6 chemotherapy regimen 65 XmAb# 65 thalidomide Thalomid 65 HGS ETR1 65 anti amnesic 65 Hedgehog inhibitor 65 ABSORB trial 65 DCCR 65 KRN# 65 Immunotherapeutic 65 OncoVEX GM CSF 65 Phase 1b 65 Afatinib 65 MEK inhibitor RDEA# 65 bazedoxifene conjugated estrogens 65 lomitapide 65 MCSP respectively 65 anticancer compound 65 MEND CABG 65 Ophena 65 Phase IIIb clinical 65 DCVax R 65 OncoGel 65 Oral NKTR 65 Matrix Phase 2b 65 LT NS# 65 TKB# 65 HDL Selective Delipidation 65 EXPLORE Xa 65 tanespimycin 65 histone deacetylase HDAC inhibitor 65 #I TM# 65 Acute Ischemic Stroke 65 RAV# 65 dose escalation Phase 65 Xelox 65 Cotara 65 Phase Ib 65 rALLy trial 65 LymphoStat B belimumab 65 DermaVir 65 paclitaxel poliglumex 65 orally dosed 65 Allovectin 7 65 pharmacodynamic properties 65 DEB# 65 Ozarelix 65 BEMA TM Fentanyl 65 talabostat 65 Metastatic Melanoma 65 Tesmilifene 65 Nanobody 65 oral ridaforolimus 65 Panzem 65 tolerability profiles 65 investigational monoclonal antibody 65 PhG alpha 1 65 PDE# inhibitors 65 bortezomib Velcade 65 antibody MAb 65 Phase 1b clinical 65 HuCAL antibodies 65 lorvotuzumab mertansine 65 Cloretazine R VNP#M 65 recurrent glioblastoma multiforme 65 CIMZIA TM certolizumab pegol 65 Antiviral Activity 65 SinuNase TM 65 dimebon latrepirdine 65 axitinib 65 Pegylated Interferon 65 Intravail ® 65 antiretroviral naïve 65 OMNARIS HFA 65 orally bioavailable 65 retaspimycin 65 JAK inhibitor 65 ADVANCE PD 65 dextofisopam 65 EndoTAG TM -1 65 protein kinase inhibitor 65 VitiGam 65 HCV NS5B polymerase 65 Diabetic Macular Edema DME 65 JAK2 inhibitors 65 Lisofylline 65 TransVax ™ 65 Hsp# inhibition 65 ATL/TV# 65 BHT DNA 65 ALN HTT 65 Dasatinib 65 Prodarsan R 65 radiation sensitizer 65 ZOLINZA 65 sapacitabine CYC# 65 ospemifene 65 SABCS 65 ISTODAX ® 65 AFREZZA TM 64 volociximab 64 novel peptide 64 Phase 2a clinical trials 64 TKM ApoB 64 acyclovir Lauriad R 64 TRV# [001] 64 DCVax ® 64 GLYX 64 Kevetrin ™ 64 ONCONASE R 64 phosphatidylserine PS targeting 64 ORMD 64 Cannabinor 64 Aryplase 64 HCD# [002] 64 Neuradiab 64 Hormone Refractory Prostate Cancer 64 ThermoDox R 64 AACR NCI EORTC 64 HGS ETR2 64 acetonide FA 64 ANG# 64 tramiprosate Alzhemed TM 64 Thiovir 64 Dacogen injection 64 Phase IIa clinical 64 RhuDex 64 CA4P 64 Syndax Pharmaceuticals Inc. 64 BMS# 64 VNP#M 64 HCV SPRINT 64 APEX PD 64 vivo validation 64 novel nucleoside analog 64 trastuzumab Herceptin R 64 NPC 1C 64 Antiangiogenic 64 essential thrombocythemia ET 64 SNT MC# 64 Hedgehog Pathway Inhibitor 64 TMC# [002] 64 SAR# [004] 64 Phase IIb III 64 IL# PE#QQR 64 lintuzumab 64 radiolabeled TM# 64 Proxinium TM 64 hereditary emphysema 64 proteasome inhibitor 64 Tezampanel 64 ritonavir boosted 64 orally inhaled migraine 64 Valortim R 64 SYN# 64 RhuDex ® 64 BRIM2 64 trastuzumab emtansine T DM1 64 rALLy 64 PANVAC VF 64 Aeolus Pharmaceuticals Announces 64 Onconase 64 KNS # 64 investigational pan BCR 64 Panzem R 64 Initiated Phase 64 Cand5 64 phase IIb III 64 CytoFabTM 64 Inotek Pharmaceuticals Corporation 64 gefitinib Iressa 64 urocortin 2 64 Proellex TM 64 XL# SAR# 64 Zosano 64 Genz # 64 compound INCB# 64 placebo controlled clinical 64 LHRH receptor positive 64 Daclizumab 64 OXi# 64 recurrent glioma 64 MGN# 64 torezolid phosphate 64 ALGRX 64 Aurexis 64 investigational HCV polymerase 64 Angiocept 64 FOLOTYN ® 64 refractory metastatic 64 clinical pharmacology studies 64 antiangiogenic activity 64 trastuzumab Herceptin 64 TAKSTA 64 EGEN 64 hA# 64 aplindore 64 lenalidomide Revlimid R 64 seliciclib CYC# 64 EndoTAG 64 immuno therapeutic 64 histone deacetylase inhibitor 64 MGd 64 Anavex #-# 64 IAP inhibitors 64 CIMZIA TM 64 human IgG1 monoclonal 64 THR beta agonist 64 Valdoxan 64 double blinded randomized 64 Aganocide 64 phase Ib clinical 64 HIV integrase inhibitors 64 Personalized Immunotherapy 64 MLN# 64 phase IIIb 64 LAB CGRP 64 Telatinib 64 targeted radiotherapeutic 64 corticosteroid dexamethasone 64 HORIZONS AMI 64 INxin TM 64 ularitide 64 MVA MUC1 IL2 64 CA9 SCAN 64 cathepsin K inhibitor 64 PEGPH# 64 DCVax ® Brain 64 stage hypoxia activated 64 Trodusquemine 64 EOquin TM 64 ANAVEX #-# [002] 64 pharmacogenetic testing 64 Phase IIb trials 64 IIa trials 64 receptor tyrosine kinase inhibitor 64 nucleoside analog 64 ART# 64 IMPDH inhibitor 64 OncoVex 64 delivers fluocinolone acetonide FA 64 metastatic castration resistant 64 Dapagliflozin 64 PF # [002] 64 HyQ 64 CCX# B 64 Akt inhibitor 64 solithromycin 64 Thiarabine 64 mapatumumab 64 ancrod 64 HuLuc# 64 Liprotamase 64 NovaBay Aganocide compounds 64 Lovaxin C 64 Temsirolimus 64 isoform selective 64 TRACON Pharmaceuticals 64 II Clinical Trial 64 randomized Phase 2b 64 Preclinical Study 64 Nanobody R 64 Ridaforolimus 64 M# rationally 64 Monoclonal antibody 64 Arikace 64 ToGA 64 ARRY # 64 bardoxolone methyl 64 BiTE R 64 Initiate Clinical Trial 64 omega interferon 64 SNALP technology 64 NVA# 64 NOX E# 64 Phase III psoriasis 64 pramlintide metreleptin combination 64 Triapine R 64 NEUGENE 64 eniluracil 63 paclitaxel Taxol ® 63 Curaxin 63 hypoxia activated prodrug 63 Vascugel 63 Cardiotoxicity 63 Alequel 63 Gastrointestinal Liner 63 TLK# 63 Cloretazine R 63 safinamide 63 EKC Cide 63 ZD# [001] 63 epigenetic therapies 63 PEGylated interferon beta 1a 63 NNR Therapeutics 63 Deforolimus 63 Zemiva TM 63 vivo efficacy 63 atherosclerosis regression 63 Fx #A 63 Vitaxin 63 Phase Ib Clinical Trial 63 Rigel R# 63 ALN VSP Phase 63 CTA# Injection 63 SUTENT ® 63 drug GAP #B# 63 GOUT 63 PDX pralatrexate 63 IIa trial 63 trastuzumab Herceptin ® 63 HGS ETR1 mapatumumab 63 viral kinetic 63 Nanobody ® 63 Smac mimetics 63 dasatinib Sprycel 63 ISF# 63 rindopepimut 63 null responder 63 ongoing Phase 1b 63 Urocortin 2 63 motesanib diphosphate 63 oral ghrelin agonist 63 Bendavia 63 angiotensin analog 63 Lisofylline LSF 63 GSK# [002] 63 mg/m2 cohort 63 Golimumab 63 cariprazine 63 anti CD# antibodies 63 MKC# MT 63 rilonacept 63 resminostat 63 Advaxis Phase 63 afamelanotide 63 alagebrium 63 Tumour Vascular Disrupting Agent 63 2 methoxyestradiol 63 aleglitazar 63 Dr. Gabriel Lasala 63 Phase 2a Clinical Trial 63 Phase Ib clinical trials 63 IIa clinical trials 63 Tasimelteon 63 BRIM3 63 PI3K inhibitor 63 olaparib 63 RNAi Therapeutic 63 viral kinetics 63 personalized immunotherapy 63 Phase 2b study 63 AEGR 63 Anthim 63 NGX# 63 randomized discontinuation trial 63 tezampanel 63 OvaRex ® MAb 63 nilotinib Tasigna 63 baminercept 63 glucokinase activator 63 NABTT 63 IMiDs ® 63 SAR# [002] 63 EVIZON 63 zanolimumab 63 DDP# 63 pharmacodynamic PD 63 candidate deforolimus 63 TOLAMBA 63 gemcitabine carboplatin 63 DPX Survivac 63 iSONEP 63 SLx 63 Aptivus ® 63 Aflibercept 63 TransVax TM 63 non nucleoside HCV 63 nucleotide analog 63 immunotherapeutic vaccine 63 SPIRIT FIRST 63 Presents Preclinical Data 63 melphalan prednisone 63 LUX Lung 63 Pharmacokinetics PK 63 tipranavir r 63 tolevamer 63 lintuzumab SGN 63 DAVANAT 63 samalizumab 63 dosing cohort 63 molecular imaging radiopharmaceutical 63 TRIST study 63 candidate TNFerade biologic 63 YONDELIS R 63 Lucanix 63 TRAIL receptor antibodies 63 trial evaluating PRX# 63 TriRima 63 Reports Preclinical Data 63 Diasome 63 SPC# [001] 63 trastuzumab DM1 63 investigational hepatitis C 63 myoblast therapy 63 CLARITY study 63 Solulin 63 Inhaled AAT 63 ALN PCS 63 AIR# [001] 63 blinded randomized placebo controlled 63 targeting CD# 63 Ostabolin C TM 63 LCP AtorFen 63 NCIC CTG 63 Liposomal 63 acadesine 63 standard chemotherapy regimen 63 #th Annual Interscience 63 Meets Primary Endpoint 63 unresectable tumors 63 ara C 63 azilsartan medoxomil 63 midstage trials 63 Phase III Clinical Trials 63 TOCOSOL Paclitaxel 63 docetaxel Taxotere R 63 sunitinib malate 63 Initiates Enrollment 63 TTF Therapy 63 Hepatotoxicity 63 Completes Patient Enrollment 63 Evoltra ® 63 OvaRex 63 Initiates Clinical Trial 63 RECORD1 63 alpha 2a 63 virus HCV protease inhibitor 63 DiLA2 63 GMX# 63 inhaled treprostinil 63 multicenter Phase III 63 Renal Cell Carcinoma RCC 63 SUCCEED trial 63 GALNS 63 ALN TTR# 63 TNFerade TM 63 bortezomib Velcade R 63 sorafenib Nexavar 63 PLK1 SNALP 63 immunotherapeutic agent 63 catheter occlusion 63 Zolpimist ™ 63 custirsen 63 PrevOnco ™ 63 HuMax CD4 63 AVOREN 63 ErbB2 positive 63 Talabostat 63 MEK Inhibitor 63 E1 INT TM 63 OX1 63 TOCOSOL Camptothecin 63 sodium thiosulfate STS 63 PKC# 63 Tanespimycin 63 statistically significant efficacy 63 cisplatin gemcitabine 63 INCB# [003] 63 ELND-#/AZD-# 63 LUMINATE 63 velafermin belinostat 63 EXPAREL ™ 63 JAK inhibitors 63 RE COVER 63 Cardioxyl Pharmaceuticals 63 Aliskiren 63 multicenter Phase 63 Cardio Vascu Grow 63 sitaxsentan 63 Campath alemtuzumab 63 ProMune 63 compound AEZS 63 Fenretinide 63 Atiprimod 63 Trastuzumab DM1 63 AQ4N 63 humanized therapeutic 63 GLPG# 63 REMINYL ® 63 ON #.Na 63 GEM OS2 63 Bionate ® PCU 63 nanoviricides 63 selective orally bioavailable 63 ZFP Therapeutics 63 Imprime PGG 63 generation NNRTI 63 Teriflunomide 63 Enzyme Replacement Therapy 63 CLORETAZINE TM VNP#M 63 AFFiRiS 63 EDEMA3 63 Microplasmin 63 PROCHYMAL 63 imetelstat 63 Clinical Antipsychotic Trials 63 CAMMS# 63 ER CHOP 63 IPL# 63 class mGluR5 inhibitor 63 MEK inhibitor 62 FluCide 62 LEUKINE 62 pharmacokinetics pharmacodynamics 62 Janus Kinase 62 Phase 2b Trial 62 Angiolix 62 beta 1a 62 multicenter phase 62 REG1 62 INT# [002] 62 5 fluorouracil leucovorin 62 Hedgehog antagonist 62 SPRYCEL ® 62 dose escalation clinical 62 resolvin 62 Zoraxel 62 JVRS 62 Anti VEGF 62 ThermoDox ® clinical 62 sipuleucel T 62 Prodarsan ® 62 EyeGate 62 Phase IIA 62 Platinol ® cisplatin 62 randomized multicenter trial 62 LHRH antagonists 62 PA# [002] 62 inhaled AAT 62 Vaxfectin R adjuvant 62 miconazole Lauriad ® 62 Locteron ® 62 CCR5 mAb 62 MAXY alpha 62 darinaparsin ZIO 62 dosing cohorts 62 lumiliximab 62 Antitumor Activity 62 bardoxolone 62 intradermal injections 62 randomized controlled Phase 62 Nanobodies ® 62 Tarvacin 62 oral FTY# 62 Relivar 62 florbetaben 62 fostamatinib 62 Adnectin 62 unique alkylating agent 62 Phase 1a 62 ® bortezomib 62 erlotinib Tarceva ® 62 vosaroxin 62 SRT# [003] 62 pharmacodynamic parameters 62 docetaxel chemotherapy 62 ocular formulation 62 Enzastaurin 62 trabedersen 62 relapsing multiple sclerosis 62 Curaxin CBLC# 62 pharmacodynamic effects 62 Sphingomab 62 pharmacokinetic PK profile 62 LY# [003] 62 latrepirdine 62 intranasal delivery 62 BNC# 62 recombinant PSMA vaccine 62 antagomirs 62 antisense inhibition 62 octreotide implant 62 Degarelix 62 Intravenous CP 62 molecular imaging radiopharmaceuticals 62 relapsed myeloma 62 taxane derivative 62 Pyridorin 62 NEUGENE antisense 62 Muraglitazar 62 eTag assays 62 intranasal formulation 62 nonclinical studies 62 BEZ# 62 HIF PHI 62 KL4 surfactant 62 Xeloda capecitabine 62 Altastaph 62 Selective Electrochemical Tumor Ablation 62 JAK2 Inhibitor 62 HCV polymerase inhibitors 62 Anticalin ® 62 colesevelam HCl 62 pDNA vaccine 62 testing huN# DM1 62 Dyloject TM 62 Gemin X 62 romidepsin 62 CIPN 62 Chemophase 62 Anticalins 62 IMC A# 62 ALK inhibitors 62 XTEN 62 Virtual Histology 62 mda 7 62 iniparib 62 pharmacokinetic PK 62 omacetaxine mepesuccinate 62 administered subcutaneously 62 CAPHOSOL 62 basal insulin analogue 62 HORIZONS AMI trial 62 initiated Phase 1b 62 proteomic biomarkers 62 AZILECT ® 62 targeted antifolate 62 Menadione 62 EndoTAGTM 1 62 Phase III Clinical Trial 62 NO# [002] 62 PSN# [001] 62 paclitaxel Taxol R 62 CANCIDAS 62 ChronVac C ® 62 Combivir Kivexa 62 Micromet BiTE 62 ReN# 62 Vacc 4x 62 XL# XL# XL# XL# 62 Actilon 62 Inhalation Solution 62 JAK1 62 Zenvia ™ 62 APTIVUS 62 gastrin analogue TT 62 Histone deacetylase 62 PERSEUS 62 gallium nitrate 62 SPIRIT IV 62 HCV Protease Inhibitor 62 Gleevec resistant 62 Preclinical Data 62 GVAX R 62 REGN# 62 IND submission 62 OnDose TM 62 Catena ® 62 hyperphenylalaninemia HPA due 62 Pervasis 62 thetreatment 62 LEVADEX ™ 62 recurrent herpes labialis 62 Ocrelizumab 62 HuMax TAC 62 LibiGel Phase III 62 BAY #-# 62 eprotirome 62 GeneICE 62 Epanova 62 Phase III Pivotal 62 Voreloxin 62 Seliciclib 62 Gastrointestinal Stromal Tumors 62 refractory gout 62 relapsed ALL 62 Xcellerated T Cells 62 oncolytic virus therapies 62 NXL# 62 docetaxel Taxotere ® 62 reslizumab 62 L BLP# 62 epoetin alpha 62 Kinase Inhibitor 62 Valortim ® 62 TASKi2 62 platform HDL Mimetic 62 HER2 positive metastatic breast 62 DUROS 62 ASONEP 62 HuMax HepC 62 Phase III Trials 62 telomerase inhibitor 62 liprotamase 62 USL# 62 tumor vascular disrupting 62 Apoptone 62 angiogenesis inhibitor 62 Onrigin 62 aldehyde dehydrogenase ALDH2 deficiency 62 dacetuzumab 62 interferon beta therapy 62 CUSTOM III 62 investigational therapies 62 dose escalation phase 62 tiapamil 62 anti angiogenic agents 62 OVATURE 62 MELAS